Australia drugmaker Mayne Pharma Group and privately held Prasco Laboratories have emerged as the latest winners in the Teva Pharmaceutical  (TEVA - Get Report) -Allergan (AGN - Get Report) generics divestiture process. 

Adelaide, Australia -based Mayne said in a June 28 announcement that that it will pay $652 million in cash for 37 approved and five FDA-filed products from Teva and Allergan. The identities of generics assets being acquired were not disclosed.  

Separately, Prasco said Tuesday it agreed to acquire the distribution rights in the U.S. for Teva's generic version of Adderall XR, a drug that treats attention deficit hyperactivity disorder, or ADHD. Financial terms of the deal were not disclosed.

While the pair of deals seem to indicate that Teva's proposed $40.5 billion deal for the U.S. generics business of Dublin-headquartered botox maker Allergan is on track, whether the companies will complete the deal within their intended June timeline remains uncertain. The deal was initially announced in July of last year. 

Coming off a June high of $249.95 a share, the latest divestitures appeared to renew sentiment in Allergan to at least some extent. Shares of the company added about 4.7% to finish Tuesday's trading session at $227.72. Teva added 2.1% to close at $49.57. 

Allergan has been pressured in recent weeks amid "investors' lack of conviction around the timing of the generics sale closing (to Teva)", and stressed by uncertainty around the Brexit situation, according to Jim Cramer, TheStreet's founder and manager of the Action Alerts PLUS portfolio, which owns Allergan shares.

"With June coming to a close, many investors have become worried that the sale has hit an impasse," Cramer said. "While the June timeline may indeed be pushed back, we believe this is more due to the backlog at the FTC and its limited resources."

"We have been working very closely with the FTC since we announced the acquisition last July and have made significant progress since that time," a Teva spokeswoman wrote Tuesday by email. "The status, as we stated in earlier this month, is that Teva has filed all of the documents with the FTC, including all contracts related to the divestitures/remedies, necessary to complete the final review. We are awaiting their final approval."

Allergan declined to comment on Tuesday, but the company's CEO Brent Saunders told attendees on June 16 at The Deal's Corporate Governance Conference in New York that the sale of its unit to Teva was in final review with the FTC and just weeks away from closing.

The two deals come after Impax Laboratories   (IPXL last week agreed to fork out $586 million for a bucket of generic drug products from Teva and Allergan. Earlier this month, Dr. Reddy's Laboratories disclosed plans to buy a portfolio of generics assets from the pharmaceutical companies in a $350 million deal.  

Mayne, an ASX-listed speciality pharmaceutical company, said it will finance the acquisition with a fully underwritten equity raising as well as through an extension of its existing debt facilities. The company said the acquired portfolio of generic assets is expected to add more than $237 million to its fiscal year 2017 net sales with gross margins greater than 50%. The deal is expected to be "significantly" accretive to its bottom line in fiscal year 2017, Mayne added. 

Having begun working with Teva and the FTC in December, Mayne noted that it has entered into supply agreements with Teva to manufacture certain products not already outsourced to CMOs (contract manufacturing organizations) for up to five years. 

Prasco Labs, a Cincinnati, Ohio-based privately held provider of branded drugs and generics products, said that it will immediately take over the distribution of the generic Adderall drug upon completion of the transaction. 

Once Teva completes its Allergan generics purchase, investors of the Israel-based pharmaceutical giant will likely shift their attention to upcoming developments within its existing pipeline. 

At the same time, Allergan will have only 1% and 5% of revenues coming from the UK and EU respectively, post-generics divestiture, noted Cramer: "This limited Brexit exposure, combined with Allergan's unmatched high-quality growth in large-cap pharma, makes AGN an attractive option (currently trading at a discount to biotech and major pharma P/E, EV/EVITDA/ and EV/Rev multiples) for those investors willing to ride out the volatility until the generics sale officially closes." 

Credit Suisse and UBS provided financial advice to Mayne on the transaction, while K&L Gates offered legal counsel and PwC provided accounting services. 

Greenhill & Co. served as financial adviser and Kirkland & Ellis served as legal counsel to Teva on its Allergan generics purchase. 

This article originally appeared in The Deal, a sister publication of focused on deals and dealmakers. For more information about The Deal click here.